Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

Autor Mian, Afsar Ali, Metodieva, Anna, Badura, Susanne, Khateb, Mamduh, Ruimi, Nili, Najajreh, Yousef, Ottmann, Oliver Gerhard, Mahajna, Jamal, Ruthardt, Martin
Vydáno 2012

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia

Autor Badura, Susanne, Tesanovic, Tamara, Pfeifer, Heike, Wystub, Sylvia, Nijmeijer, Bart A., Liebermann, Marcus, Falkenburg, J. H. Frederik, Ruthardt, Martin, Ottmann, Oliver G.
Vydáno 2013

SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment

Autor Demirel, Özlem, Balló, Olivier, Reddy, Pavankumar N. G., Vakhrusheva, Olesya, Zhang, Jing, Eichler, Astrid, Fernandes, Ramona, Badura, Susanne, Serve, Hubert, Brandts, Christian
Vydáno v PLoS One (2017)

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Autor Lang, Fabian, Wunderle, Lydia, Badura, Susanne, Schleyer, Eberhard, Brüggemann, Monika, Serve, Hubert, Schnittger, Susanne, Gökbuget, Nicola, Pfeifer, Heike, Wagner, Sebastian, Ashelford, Kevin, Bug, Gesine, Ottmann, Oliver G.
Vydáno v BMC Pharmacol Toxicol (2020)